Skip to main content

ALLO

Stock
Health Care
Biotechnology

Performance overview

ALLO Price
Price Chart

Forward-looking statistics

Beta
2.18
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research and development efforts.

Company info

SectorHealth Care
IndustryBiotechnology
Employees370
Market cap$484.4M

Fundamentals

Enterprise value$56.0M
Revenue$22.0K
Revenue per employee
Profit margin0.00%
Debt to equity23.07

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$1.22
Dividend per share
Revenue per share$0.00
Avg trading volume (30 day)$3M
Avg trading volume (10 day)$4M
Put-call ratio

Macro factor sensitivity

Growth+1.1
Credit-13.7
Liquidity+5.3
Inflation+3.1
Commodities+0.5
Interest Rates-3.5

Valuation

Dividend yield0.00%
PEG Ratio-0.86
Price to sales11831.36
P/E Ratio-0.86
Enterprise Value to Revenue2547.54
Price to book0.67

Upcoming events

Next earnings dayMay 14, 2025
Next dividend day
Ex. dividend day

News

Why Is Allogene Therapeutics (ALLO) Up 52.2% Since Last Earnings Report?

Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research (June 12, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free